COVID-19 Drug Associated APIs Market Report 2023

COVID-19 Drug Associated APIs Global Market Report 2023 – By Drug Class (Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class), By Synthesis Type (Synthetic, Biotech), By Business Mode (Captive API, Merchant API) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format :

Need assistance or more information before the purchase?

Enquire Before Buying
COVID-19 Drug Associated APIs Market

Proud Members Of

COVID-19 drug-associated APIs refer to the active pharmaceutical components that are employed in the production of COVID-19 medications. Chemicals called "active pharmaceutical components" serve as the foundation for pharmaceutical drugs and medicines and are responsible for pharmacological activity in the human body.

The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals, and others. Antimalarial drugs, or simply "antimalarials," are antiparasitic chemical agents that can be used to cure or prevent malaria. They are generally organically sourced. The different types of drugs include generic, branded, and involve various modes of business such as captive API and merchant API.

The global COVID-19 drug associated apis market is segmented -

1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class

2) By Synthesis Type: Synthetic, Biotech

3) By Business Mode: Captive API, Merchant API

The global COVID-19 drug associated APIs market size grew from $5.99 billion in 2022 to $6.37 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the COVID-19 drug associated APIs market is expected to grow from $8.02 billion in 2027 at a CAGR of 5.9%.

High demand for some antiretrovirals, antimalarials, sedatives, bronchodilators and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active component used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. Remdesivir received emergency use authorization (EUA) from the FDA on May 1, 2020, based on its preliminary data showing a faster time to recovery in hospitalised patients with several diseases. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19 drug associated APIs market over the forecast period.

Major players in the COVID-19 drug-associated APIs market report are Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co. Ltd., and Yatai Pharma.

The disruptions caused by the COVID-19 outbreak in the supply chain of medical products limited the growth of the COVID-19 drug-associated APIs market in the past few months. The source for APIs plays a crucial part in the strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, with nearly 30% of generic APIs used in the USA. The restrictions imposed on the export of pharmaceutical products owing to COVID-19 supply chain disruptions restricted market growth. For instance, India imposed an export ban on 26 pharmaceutical products and medical devices in March 2020. The ban was imposed due to API and other bulk drug supply chain disruptions caused by restrictive measures such as lockdowns and factory closures in many countries around the world to ensure disease containment.Thus, shortages caused by disruptions in supply chains and restrictions imposed on the export of pharma products impacted the growth of the COVID-19 drug-associated APIs market over the last few months.

Key players operating in the pharmaceutical industry that manufactures COVID-19 drug-associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in March 2020, Alembic Pharmaceuticals Ltd announced that the company is ramping up the production for the company’s production for azithromycin to 20 tonnes per month. Likewise, In April 2020, FUJIFILM Corporation announced the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan Tablet (Favipiravir) by nearly 2.5 times by the end of July. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients.

In February 2020, Dr. Reddy Labs announced the acquisition of the branded generics business of Wockhardt for an amount of $242 million (INR 1,850 crore). The acquisition is expected to scale up the former company’s presence in home markets including India, Nepal, Sri Lanka, Bhutan, and the Maldives. The Wockhardt business consists of a product portfolio of 62 brands in multiple therapy fields such as dermatology, neurology, respiratory, VMS, pain, gastroenterology, and vaccine. Wockhardt Ltd. was founded in 1999 and is a global biotechnology and pharmaceutical company based in Mumbai, India.

North America is the largest region in the COVID-19 drug-associated APIs market in 2022. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market share during the forecast period. The regions covered in the COVID-19 drug-associated APIs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the COVID-19 drug-associated APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The COVID-19 drug-associated APIs market research report is one of a series of new reports from The Business Research Company that provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, COVID-19 drug-associated APIs market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. COVID-19 Drug Associated APIs Market Characteristics

    3. COVID-19 Drug Associated APIs Market Trends And Strategies

    4. COVID-19 Drug Associated APIs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On COVID-19 Drug Associated APIs Market

    4.2 Ukraine-Russia War Impact On COVID-19 Drug Associated APIs Market

    4.3 Impact Of High Inflation On COVID-19 Drug Associated APIs Market

    5. COVID-19 Drug Associated APIs Market Size And Growth

    5.1. Global COVID-19 Drug Associated APIs Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global COVID-19 Drug Associated APIs Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. COVID-19 Drug Associated APIs Market Segmentation

    6.1. Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Antimalarials

    Bronchodilators

    Antibiotics

    Antivirals

    Other Drug Class

    6.2. Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Synthetic

    Biotech

    6.3. Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Captive API

    Merchant API

    7. COVID-19 Drug Associated APIs Market Regional And Country Analysis

    7.1. Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific COVID-19 Drug Associated APIs Market

    8.1. Asia-Pacific COVID-19 Drug Associated APIs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China COVID-19 Drug Associated APIs Market

    9.1. China COVID-19 Drug Associated APIs Market Overview

    9.2. China COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India COVID-19 Drug Associated APIs Market

    10.1. India COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan COVID-19 Drug Associated APIs Market

    11.1. Japan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia COVID-19 Drug Associated APIs Market

    12.1. Australia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia COVID-19 Drug Associated APIs Market

    13.1. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea COVID-19 Drug Associated APIs Market

    14.1. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe COVID-19 Drug Associated APIs Market

    15.1. Western Europe COVID-19 Drug Associated APIs Market Overview

    15.2. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK COVID-19 Drug Associated APIs Market

    16.1. UK COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany COVID-19 Drug Associated APIs Market

    17.1. Germany COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France COVID-19 Drug Associated APIs Market

    18.3. France COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe COVID-19 Drug Associated APIs Market

    19.1. Eastern Europe COVID-19 Drug Associated APIs Market Overview

    19.2. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia COVID-19 Drug Associated APIs Market

    20.1. Russia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America COVID-19 Drug Associated APIs Market

    21.1. North America COVID-19 Drug Associated APIs Market Overview

    21.2. North America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA COVID-19 Drug Associated APIs Market

    22.1. USA COVID-19 Drug Associated APIs Market Overview

    22.2. USA COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America COVID-19 Drug Associated APIs Market

    23.1. South America COVID-19 Drug Associated APIs Market Overview

    23.2. South America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil COVID-19 Drug Associated APIs Market

    24.1. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East COVID-19 Drug Associated APIs Market

    25.1. Middle East COVID-19 Drug Associated APIs Market Overview

    25.2. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa COVID-19 Drug Associated APIs Market

    26.1. Africa COVID-19 Drug Associated APIs Market Overview

    26.2. Africa COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. COVID-19 Drug Associated APIs Market Competitive Landscape And Company Profiles

    27.1. COVID-19 Drug Associated APIs Market Competitive Landscape

    27.2. COVID-19 Drug Associated APIs Market Company Profiles

    27.2.1. Dr. Reddy's Laboratories

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Lianyungang Guike Pharmaceutical

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Alembic Pharmaceutical

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Wockhardt Ltd

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Sandoz Srl

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. COVID-19 Drug Associated APIs Pipeline Analysis

    29. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market

    30. COVID-19 Drug Associated APIs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: China, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: India, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: UK, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: France, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: North America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: USA, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: South America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Dr. Reddy's Laboratories Financial Performance
  • Table 28: Lianyungang Guike Pharmaceutical Financial Performance
  • Table 29: Alembic Pharmaceutical Financial Performance
  • Table 30: Wockhardt Ltd Financial Performance
  • Table 31: Sandoz Srl Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: China, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: India, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: UK, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: France, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: North America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: USA, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: South America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Dr. Reddy's Laboratories Financial Performance
  • Figure 28: Lianyungang Guike Pharmaceutical Financial Performance
  • Figure 29: Alembic Pharmaceutical Financial Performance
  • Figure 30: Wockhardt Ltd Financial Performance
  • Figure 31: Sandoz Srl Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report